Mitochondria-Targeted Nanozyme Triggers Dual Cancer Cell Death Pathways
Novel nanoplatform delivers copper and iron ions to trigger both ferroptosis and cuproptosis in cancer cells.
Summary
Researchers developed a dual-metal nanoplatform that simultaneously delivers copper ions to mitochondria and iron ions to cancer cells, triggering two distinct cell death pathways: ferroptosis and cuproptosis. The mitochondria-targeted Cu1.8S nanodots showed enhanced cancer cell killing compared to non-targeted versions, while the iron-based framework provided additional oxidative stress. This multi-pathway approach overcame cancer cell resistance mechanisms and demonstrated significant anti-tumor effects in laboratory studies.
Detailed Summary
Cancer cells often develop resistance to single-pathway treatments, making combination therapies increasingly important. This study introduces a novel nanoplatform that simultaneously disrupts iron and copper homeostasis to trigger two distinct cell death mechanisms: ferroptosis (iron-dependent) and cuproptosis (copper-dependent).
Researchers created MIL-Cu1.8S-TPP/FA nanoparticles by combining copper sulfide nanodots with an iron-based metal-organic framework. The copper component was modified with triphenylphosphine (TPP) for mitochondrial targeting, while folic acid (FA) enabled cancer cell recognition. In 4T1 breast cancer cells, mitochondria-targeted Cu1.8S-PEG-TPP reduced cell viability to 37.61% at 100 μg/mL, significantly outperforming non-targeted versions.
The platform worked through multiple mechanisms: copper ions disrupted mitochondrial iron-sulfur proteins (reducing FDX-1 levels while increasing stress protein HSP70), while iron ions catalyzed reactive oxygen species generation through Fenton reactions. This dual approach overwhelmed cellular antioxidant defenses, including the GPX4-GSH system that normally protects against ferroptosis.
Density functional theory analysis confirmed enhanced catalytic activity of the iron-copper heterojunction, with improved H2O2 adsorption and lower energy barriers for peroxidase-like reactions. The nanoparticles also retained photothermal properties, allowing near-infrared light to enhance treatment effects. Treatment with copper chelators or mitochondrial inhibitors rescued cell viability, confirming the cuproptosis mechanism.
This research demonstrates how precise subcellular targeting can enhance therapeutic efficacy. By delivering metals to specific organelles and exploiting multiple cell death pathways simultaneously, this approach may overcome resistance mechanisms that limit current cancer treatments.
Key Findings
- Mitochondria-targeted Cu1.8S-PEG-TPP reduced cancer cell viability to 37.61% vs minimal toxicity of non-targeted versions at 100 μg/mL
- Treatment significantly decreased FDX-1 protein levels and increased HSP70 expression, confirming cuproptosis pathway activation
- Iron-copper heterojunction showed enhanced H2O2 adsorption and lower energy barriers for peroxidase reactions vs individual components
- Copper chelator TTM and mitochondrial inhibitors antimycin A/rotenone rescued cell viability, confirming copper-dependent mechanism
- Platform generated significantly higher intracellular ROS levels compared to individual metal components
- Nanoparticles maintained photothermal conversion properties with wide NIR absorption (700-1100 nm)
- Secondary growth method produced uniform 300×170 nm particles with surface-exposed copper nanodots
Methodology
Researchers used 4T1 mouse breast cancer cells and MDA-MB-231 human breast cancer cells to test the nanoplatform. Cell viability was assessed via CCK-8 assays after 24-hour treatments. Protein expression was analyzed by Western blot and mass spectrometry. ROS generation was measured using confocal microscopy and flow cytometry. Mechanism validation used specific inhibitors including copper chelator TTM and mitochondrial complex inhibitors.
Study Limitations
This is an early-stage preclinical study conducted only in cell culture models. The research lacks in vivo efficacy and safety data in animal models. Long-term biocompatibility and potential accumulation effects of the metal nanoparticles are not addressed. The study does not compare efficacy against standard cancer treatments or evaluate effects on normal healthy cells.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.